全球足底筋膜炎治療市場-2022-2029

市場概況

在預測期間（2022-2029 年），足底筋膜炎治療市場預計將以 4.2% 的複合年增長率增長。

足底筋膜炎是足底筋膜的炎症，足底筋膜是支撐足底足弓的纖維組織帶。當該組織帶超載或拉伸時會發生這種情況。小撕裂，尤其是筋膜與跟骨相交處。足底筋膜炎在肥胖人群和孕婦中很常見，超重會使脆弱的足底筋膜超負荷。它在糖尿病患者中也很常見，但確切原因尚不清楚。

市場動態

預計足底筋膜炎患者數量的增加將推動預測期內足底筋膜炎治療市場的增長。

矯形技術的日益普及以及足底筋膜炎患者的增加是全球市場增長的主要驅動力之一。根據美國國家衛生統計中心 (NCHS) 的數據，估計全世界每年約有 200 萬人患有足底筋膜炎。走路姿勢不當、運動量突然增加、長時間站立、負重、鞋子不合腳等都會誘發足底筋膜微撕裂，導致足底筋膜炎。

此外，肥胖的增加也有望推動足底筋膜炎治療市場的增長。

老年人和肥胖的人更容易患足底筋膜炎。足底筋膜炎會導致足底筋膜（連接足跟和腳趾骨的組織）變得僵硬且更具抑制性，從而導致劇烈疼痛和其他並發症。

根據世界衛生組織 (WHO) 的數據，2016 年有超過 19 億 18 歲以上的成年人超重。其中，超過 6.5 億人肥胖。2016 年，39% 的 18 歲以上成年人超重，13% 肥胖。世界上大多數人口生活在超重和肥胖造成的死亡人數多於體重不足死亡人數的國家。2019 年，有 3800 萬五歲以下兒童被發現超重或肥胖。2016 年，超過 3.4 億 5-19 歲的兒童和青少年超重或肥胖。

久坐不動的生活方式的增加以及飲食習慣的改變導致肥胖增加，這會對關節和腳踝造成壓力並導致足底筋膜炎。

高治療成本阻礙市場增長

然而，高昂的治療費用和對足底筋膜炎的低認識正在阻礙市場增長。市場增長預計也將受到製造有效治療醫療設備所需原材料價格波動的阻礙。此外，也有人擔心製造商庫存和原材料大，產品盈利能力下降，這可能會限制市場增長。

流行病學

足底筋膜炎在美國非常普遍，據說每年有數百萬人經歷足跟痛。足底筋膜炎可由多種原因引起，但大多數情況下是由過度使用造成的壓力引起的。據估計，每年有超過 200 萬美國人接受足底足跟痛的治療。現役軍人和文職僱員中的流行率特別高。在全球範圍內，報告的足底筋膜炎發病率在運動員和非運動員中均約為 10%。

足底近端筋膜炎患者的平均年齡約為 45 歲。還有一個已知的性別差異，近端足底筋膜炎在女性中的發生率是男性的兩倍。

足底筋膜炎約佔跑步者相關損傷的 10%，佔所有需要專科護理的足部疾病的 11% 至 15%。大約 10% 的普通人群受到影響，其中 83% 是年齡在 25 至 65 歲之間的在職工作成年人。

市場細分

按治療類型，全球市場分為藥物療法、支具療法、衝擊波療法、手術等。

矯形器部分在預測期內主導全球足底筋膜炎治療市場

支具是一種支具，用於在行走或跑步時支撐虛弱的肌肉。這些裝置還可以提高舒適度並減緩攣縮的進展。這些可以在白天或晚上的任何時間佩戴。牙套的使用取決於患者問題的類型。常見的支具包括膝踝支具和踝足支具。

足底筋膜炎通常是由扁平足引起的，這使得它們看起來更大。更換足弓結構是減輕足部負擔的有效方法之一。對於那些患有足底筋膜炎不適的人來說，支具可能是一個有價值的解決方案。因此，為了滿足消費者的需求，市場參與者正專注於開發各種新型和技術先進的矯形器，這些矯形器有望推動整個市場。

在預測期內，治療型沖擊波治療部分預計將以最快的複合年增長率增長。

衝擊波療法市場分為體外衝擊波療法和內部氣動衝擊波療法。足底筋膜炎是一種日益常見的足部疼痛疾病，並且在全球範圍內進行越來越多的治療。體外衝擊波療法將聲波引導到腳後跟的疼痛區域以促進癒合。它通常用於對保守治療無反應的慢性足底筋膜炎。一些研究顯示了有希望的結果，但它們並非始終有效。

預計藥物治療在預測期內將顯著增長

藥物治療很有幫助，因為它最初會加重疼痛，尤其是當患者開始進行伸展運動時。

用於治療足底筋膜炎的藥物包括：

鎮痛劑：鎮痛劑可確保患者舒適，促進肺部如廁，具有鎮靜作用，對創傷和受傷患者有效。

對乙□氨基酚（不含阿司匹林的 Anacin、Feverall、Tylenol）可有效緩解輕度至中度的急性疼痛。然而，它沒有外周抗炎活性。

非甾體抗炎藥。非甾體抗炎藥具有鎮痛和解熱作用。它抑制其白三烯合成、溶□體□釋放、脂氧合□活性、中性粒細胞聚集和各種細胞膜功能。

布洛芬（Advil、Excedrin IB、Motrin、Ibuprin）用於輕度至中度疼痛的患者。它通過減少前列腺素的合成來抑制炎症反應和疼痛。

酮洛芬（Actron、Orudis、Oruvail）：用於緩解輕度至中度疼痛和炎症。小型、老年人和患有腎臟或肝臟疾病的人適用於初始低劑量給藥。

□普生（Aleve、Anaprox、Naprelan、Naprosyn）：輕度至中度疼痛緩解；通過降低負責前列腺素合成的環氧合□的活性來抑制炎症反應和疼痛。非甾體抗炎藥可降低腎小球內壓力並減少蛋白尿。

按最終用戶劃分，它分為醫院、門診手術中心、診所等。

醫院主導全球足底筋膜炎藥物市場

由於在醫院進行的外科手術數量不斷增加，醫院部門在 2019 年的收入方面佔市場的主要份額。藥物療法越來越受到關注，因為它是治療足底筋膜炎相關症狀（如炎症和疼痛）最廣泛採用的治療方法。然而，很少有人需要手術將足底筋膜與跟骨分開。通常僅在疼痛嚴重且其他治療失敗時才選擇手術。手術通過開放手術或局部麻醉下的小切口進行。

地理特徵

足底筋膜炎治療將在 2021 年佔據北美最大的市場份額，增加對開發新治療方案的投資、大量患有足痛疾病的人口基數以及不斷擴大的分銷網絡。預計在預測期內將顯著增長.在美國，足底筋膜炎的患病率正在迅速增加。例如，美國足病醫學協會 (APMA) 的一項調查顯示，77% 的美國人患有足部疼痛。這意味著美國約有 200 萬人患有足底筋膜炎，這是最常見的足部疼痛類型之一。此外，美國肥胖症的增加和生活方式的改變正在推動市場的增長。根據國家臨床試驗 (NCT) 登記處的數據，截至 2020 年 6 月 18 日，美國正在招募大約六項不同發展階段的臨床試驗，用於治療足底筋膜炎。

競爭格局

世界市場得到鞏固。幾家新興市場公司專注於開發價格合理且易於使用的新產品並將其推向市場。例如，2021 年 9 月 28 日，FDA 批准了衝擊波療法治療足底筋膜炎。衝擊波療法有兩種類型：聚焦衝擊波和輻射壓力波。

足底筋膜炎治療市場競爭適度，由幾個主要參與者組成。為市場增長做出貢獻的主要參與者包括A.Algeo Limited、Superfeet Worldwide, Inc.、Hanger, Inc.、Bayer Group（□）、GlaxoSmithKline Plc、Bauerfeind AG、Pfizer, Inc、Sanofi、Ottobock SE &Co.、KGaA.（Ottobock Holding）等

領先的公司正在採取多種增長戰略，例如產品發布、收購和合作夥伴關係，這有助於全球市場的增長。例如：

產品發布 2021 年 8 月 24 日，Superfeet Worldwide LLC 推出了 ADAPT run 系列鞋墊。該系列已獲得自適應舒適技術的專利。這些跑步鞋墊有兩種足弓高度可供選擇。ADAPT Run 是細低足弓，而 ADAPT Run Max 是深跟杯和高足弓。

Pfizer Inc.

概述

Pfizer Inc.是世界領先的創新生物製藥公司之一，每年發現、開發和提供 170 多種藥物和疫苗保健產品，改善英國和世界各地數百萬人的生活。

產品介紹

DEPO-MEDRONE(R) (METHYLPREDNISOLONE ACETATE) Depot-medron 含有醋酸甲基強的松龍。甲基強的松龍屬於一組稱為皮質類固醇或類固醇的藥物。腎上腺皮質類固醇是您體內自然產生的，對許多身體功能都很重要。

目錄

第一章 調查方法和範圍

• 調查方法
• 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

• 按治療類型劃分的市場細分
• 最終用戶的市場細分
• 區域市場細分

第四章市場動態

• 市場影響因素
  • 促進者
    • 開發先進的足底筋膜炎治療產品和解決方案
    • 隨著肥胖症的增加，足底筋膜炎病例不斷增加
  • 抑製劑
    • 治療費用高
  • 商機
  • 影響分析

第五章行業分析

• 流行病學
• 管道分析
• 波特五力分析
• 供應鏈分析
• 臨床試驗
• 定價分析
• 法律法規分析
• 保險報銷分析
• 未滿足的需求

第 6 章 COVID-19 分析

• COVID-19 的市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 中的價格動態
• 供需譜
• 大流行期間與市場相關的政府努力
• 製造商的戰略舉措
• 概括

第 7 章 按治療類型

• 手術
• 衝擊波療法
  • 體外衝擊波療法（ESWT）
  • 體外氣動衝擊波治療 (IPST)
• 藥物治療
  • 止痛藥
  • 對乙□氨基酚（阿司匹林、游離Anacin、Feverall、Tylenol）等。
  • 非甾體抗炎藥（NSAIDs）
  • 布洛芬（Advil、Excedrin IB、Motrin、布普林）
  • 酮洛芬（Actron、Orudis、Oruveil）
  • □普生（Aleve、Anaprox、Naplelan、Naprosyn）
  • 其他
• 支撐
• 其他治療劑

第 8 章最終用戶

• 醫院
• 骨科診所
• 其他

第9章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 亞太其他地區
• 中東/非洲

第 10 章 競爭格局

• 競爭情景
• 市場/份額分析
• 併購分析

第十一章公司簡介

• Pfizer, Inc.
  • 公司簡介
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• Shapecrunch Technology Pvt Ltd
• Hanger, Inc.
• A. Algeo Limited
• Bauerfeind AG
• Ottobock SE & Co. KGaA（Ottobock Holding）
• GlaxoSmithKline plc
• Sanofi
• Bayer Group（Dr. Scholl's）
• Superfeet Worldwide, Inc.（*LIST NOT EXHAUSTIVE）

第 12 章 重要注意事項

第 13 章 數據管理

Market Overview

The Plantar Fasciitis Treatment Market is expected to grow at a high CAGR of 4.2% during the forecasting period (2022-2029).

Plantar fasciitis is an inflammation of the plantar fascia which is a fibrous band of tissue on the bottom of the foot which supports the arch. It occurs when this band of tissue is overloaded or overstretched. This causes small tears in the fibers of the fascia, especially where the fascia meets the heel bone. Plantar fasciitis is common in obese people and pregnant women, their extra body weight overloads the delicate plantar fascia. It is also common in people with diabetes, although the exact reason for this is unknown.

Market Dynamics

The increasing number of plantar fasciitis cases is expected to drive the plantar fasciitis treatment market growth over the forecast period

Increasing adoption of orthotics techniques coupled with rising cases of plantar fasciitis is among the major factors driving the market growth globally. As per the National Center for Health Statistics (NCHS), it is estimated that about two million population suffers from plantar fasciitis annually worldwide. Incorrect walking posture, a sudden rise in sports activities, prolonged standing, weight-bearing, ill-fitted shoes can trigger micro-tears in the plantar fascia, and result in plantar fasciitis.

Increasing incidences of obesity are also expected to drive plantar fasciitis treatment market growth

Geriatric. and obese people are more prone to plantar fasciitis. It leads to sharp pain and other complications, in which, plantar fascia, a tissue connecting the heel and the toe bones becomes less flexible and more constrained.

As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population live in countries where overweight and obesity kill more people than underweight. Thirty-eight million children under the age of 5 were overweight or obese in 2019. Over 340 million children and adolescents aged 5-19 were overweight or obese in 2016.

An increase in the number of individuals living sedentary lifestyles along with changes in eating habits leads to a rise in obesity, which puts pressure on the joints and ankles and can result in plantar fasciitis.

The high cost of treatment is hampering the market growth

However, the high cost of the treatment and lack of awareness about the plantar fasciitis condition is hampering the growth of the market. Also, the lack of stable raw materials pricing for the production of effective therapeutic medical devices is expected to hinder the growth of the market. Some concerns regarding the decline in profitability ratio for the products amid the availability of large inventory and raw material stock with the manufacturers are expected to restrict the market growth.

Epidemiology

Plantar fasciitis is very common in the US, with millions experiencing heel pain every year. The cause of plantar fasciitis is multifactorial, but most cases result from overuse stress. It is estimated that over two million Americans seek treatment for plantar heel pain each year. The prevalence of active and military populations is especially high. Globally, in both athletic and nonathletic populations, the incidence of plantar fasciitis is reported to be approximately 10%.

The average age of a patient with proximal plantar fasciitis is around 45 years. There is also known sex-based dimorphism in presentation, with proximal plantar fasciitis being twice as common in women as in men.

Plantar fasciitis accounts for about 10% of runner-related injuries and 11% to 15% of all foot symptoms requiring professional medical care. It occurs in about 10% of the general population as well, with 83% of these patients being active working adults between the ages of 25 and 65 years old.

Market Segmentation:

By treatment type, the global market is classified into medication therapy, orthotics, shockwave therapy, surgery, and others.

The orthotic devices segment is dominating the global plantar fasciitis treatment market over the forecast period

Orthotic devices, also known as orthoses, are the type of braces that supports weakened muscles while walking or running. These devices also improve comfort and slow down the progress of contractures. These can be worn at any time of the day or night. The use of an orthotic device depends on the patient's type of concern. The common types of orthotic devices include knee-ankle-foot orthoses and ankle-foot orthoses.

Plantar fasciitis commonly occurs as a result of flattening of the foot, which makes the foot appear larger. One of the best ways to ease the burden on the foot is by essentially replacing the structure of the arch. Orthotics are a valuable solution for people struggling with the discomfort of plantar fasciitis. Hence, to reach consumer requirements, market players are focusing on developing different novel and technologically advanced orthotic devices which are anticipated to propel the overall market.

The Shockwave therapy segment of treatment type is expected to grow at the fastest CAGR over the forecast period

The shockwave therapy market is segmented into extracorporeal shock wave therapy and intracorporeal pneumatic shockwave therapy. Plantar fasciitis is growing due to increasing common foot pain conditions which has also raised the number of treatments globally. In Extracorporeal shock wave therapy, sound waves are directed at the area of heel pain to stimulate healing. It is commonly used for chronic plantar fasciitis that hasn't responded to more-conservative treatments. Some studies show promising results, but it isn't consistently effective.

Medication therapy is expected to grow significantly over the forecast period

Medication is useful in the early stages, especially if the patient has begun stretching exercises, because, initially, these can worsen the pain.

Some of the medications used for the treatment of plantar fasciitis are:

Analgesics: Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or who have sustained injuries.

Acetaminophen (Aspirin Free Anacin, Fever all, Tylenol) is effective in relieving mild to moderate acute pain; however, it has no peripheral anti-inflammatory effects.

Nonsteroidal Anti-inflammatory Drugs: NSAIDs have analgesic and antipyretic activities. They inhibit its leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.

Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin) are used for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Ketoprofen (Actron, Orudis, Oruvail): For the relief of mild to moderate pain and inflammation. Small initial dosages are indicated in small and elderly patients and those with renal or liver disease.

Naproxen (Aleve, Anaprox, Naprelan, Naprosyn): For the relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which is responsible for prostaglandin synthesis. NSAIDs decrease intraglomerular pressure and decrease proteinuria.

By end-user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others.

Hospitals are contributing to the majority of the market share in the global market for plantar fasciitis treatment

The hospital's segment held the major share of the market in terms of revenue in 2019 due to the rising number of surgeries for treatment, which takes place in hospitals. Medication therapy has gained traction due to the most widely adopted line of therapy to manage symptoms related to plantar fasciitis like inflammation and pain. However, few people need surgery to detach the plantar fascia from the heel bone. Surgery is generally an option only when the pain is severe, and other treatments have failed. It can be done as an open procedure or through a small incision with local anesthesia.

Geographical Presentation:

North America holds plantar fasciitis treatment accounted for the largest market share in 2021, and is expected to grow significantly over the forecast period, due to increasing investments in the development of new treatment options, large population base with foot pain conditions, and expansion in the distribution networks. The prevalence rates of plantar fasciitis are growing rapidly in the United States. For instance, as per the American Podiatric Medical Association (APMA), research study revealed that 77 percent of Americans suffer from the foot pain. It is Approximately 2 million people in the United States will suffer from Plantar Fasciitis, one of the most common foot pains. Also, the rise in the number of obese people in the United States and changing lifestyle is driving the growth of the market. As per the National Clinical Trials (NCT) registry, as of June 18, 2020, currently, there are about 6 recruiting clinical trials across different phases of development for the treatment of Plantar Fasciitis in the United States.

Competitive Landscape:

The global market is consolidated. Several private companies are focusing on the development and introduction of novel products into the market, which are easily affordable and accessible. For instance, on 28th September 2021, the FDA approved Shock wave therapy treatment for plantar fasciitis. There are two types of shock wave therapies: focused shock waves and radial pressure waves.

The plantar fasciitis treatments market is moderately competitive and consists of several major players. Some of the key players which are contributing to the growth of the market include A. Algeo Limited, Superfeet Worldwide, Inc., Hanger, Inc., Bayer Group (Dr. Scholl's), GlaxoSmithKline Plc, Bauerfeind AG, Pfizer, Inc., Sanofi, and Ottobock SE & Co., KGaA. (Ottobock Holding), among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance,

Product Launch: On 24th August 2021, Superfeet Worldwide LLC launched ADAPT run collection of insoles. This collection is patented under Adaptive Comfort Technology. These running insoles are available in two arch heights: ADAPT Run with a thinner profile and lower arch and ADAPT Run Max with a deeper heel cup and higher arch profile.

Pfizer, Inc.

Overview:

Pfizer is one of the world's premier innovative biopharmaceutical companies, discovering, developing, and providing over 170 different medicines and vaccines healthcare products to help improve the lives of millions of people in the UK and around the world every year.

Product Portfolio:

DEPO-MEDRONE® (METHYLPREDNISOLONE ACETATE) Depo-Medrone contains methylprednisolone acetate. Methylprednisolone belongs to a group of medicines called corticosteroids or steroids. Corticosteroids are produced naturally in your body and are important for many body functions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Treatment Type
• 3.2. Market Snippet by End-User
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Development of technically advanced products and solutions for treatment of plantar fasciitis
    • 4.1.1.2. Rising cases of plantar fasciitis couple with increasing obesity
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Epidemiology
• 5.2. Pipeline Analysis
• 5.3. Porter's Five Forces Analysis
• 5.4. Supply Chain Analysis
• 5.5. Clinical Trials
• 5.6. Pricing Analysis
• 5.7. Regulatory Analysis
• 5.8. Reimbursement Analysis
• 5.9. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
• 7.3. Market Attractiveness Index, By Treatment Type Segment
  • 7.3.1. Surgery*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Shockwave Therapy
    • 7.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 7.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 7.3.3. Medication Therapy
    • 7.3.3.1. Analgesics
    • 7.3.3.1.1. Acetaminophen (Aspirin Free Anacin, Feverall, Tylenol)
    • 7.3.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 7.3.3.2.1. Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin)
    • 7.3.3.2.2. Ketoprofen (Actron, Orudis, Oruvail)
    • 7.3.3.2.3. Naproxen (Aleve, Anaprox, Naprelan, Naprosyn)
    • 7.3.3.3. Others
  • 7.3.4. Orthotics
  • 7.3.5. Other treatments

8. By End-User

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
• 8.3. Market Attractiveness Index, By End-User Segment
  • 8.3.1. Hospitals*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Orthopedic Clinics
  • 8.3.3. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Shapecrunch Technology Pvt Ltd
• 11.3. Hanger, Inc.
• 11.4. A. Algeo Limited
• 11.5. Bauerfeind AG
• 11.6. Ottobock SE & Co. KGaA (Ottobock Holding)
• 11.7. GlaxoSmithKline plc
• 11.8. Sanofi
• 11.9. Bayer Group (Dr. Scholl's)
• 11.10. Superfeet Worldwide, Inc.(*LIST NOT EXHAUSTIVE)

12. Premium Insights

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us